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Abstract
Background and Purpose—Apolipoprotein E genotype (APOE) influences cholesterol levels
and ischemic heart disease. Although there is no convincing overall association with ischemic
stroke, APOE may influence large artery (atherothrombotic) stroke, for which carotid intima-
media thickness (CIMT) is an informative intermediate phenotype. We therefore performed a
systematic review and meta-analysis of the association between APOE and CIMT.
Methods—We sought all published studies assessing the association between APOE and CIMT.
From each study, we extracted available data on study methods, subjects’ characteristics, and
mean (and standard deviation) CIMT for each genotype or genotype group. We calculated study-
specific and random effects pooled differences in mean CIMT between genotype groups, and
assessed heterogeneity between studies and predefined subgroups using I2 and χ2 statistics.
Results—Meta-analysis of 22 published studies (30 879 subjects) showed a significant
association between APOE and CIMT (pooled mean difference ε4-versus ε2-allele containing
genotypes 46 μm, 95% CI 29 to 62, P<0.00001). We found evidence of small study (mainly
publication) bias, with a diminished (but still highly statistically significant) association in studies
of >1000 subjects (pooled mean difference 17 μm, 95% CI 12 to 23, P<0.00001). The association
was larger among high vascular risk and eastern Asian populations, but this may simply reflect the
smaller size of these studies.
Conclusion—Our results show a clear association of APOE with CIMT, even though
publication bias means that this is overestimated by the published literature. These findings
suggest the possibility of a specific association with large artery ischemic stroke.
Keywords
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Twin and family history studies have shown that the incidence of ischemic stroke is likely to
be influenced by genetic factors.1 However, case-control candidate gene association studies
have so far had limited success in consistently identifying potentially causative genes.2-4
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Inadequate study size, control selection bias, and lack of distinction between different
ischemic stroke subtypes have all been suggested as reasons.4,5
The apolipoprotein E gene (apoE=protein, APOE=gene) is a widely studied gene in vascular
and neurodegenerative diseases, including stroke.4,6 Its protein product, the glyco-protein
apoE, has 3 common isoforms, E2, E3 and E4, encoded by the alleles ε2, ε3 and ε4, giving
rise to 6 genotypes, with ε3/ε 3 occurring in about one half to two thirds of people in most
populations. The 3 common protein isoforms interact differently with specific lipoprotein
receptors, ultimately altering circulating levels of cholesterol through different effects on
lipoprotein metabolism, mediated through the hepatic binding, uptake, and catabolism of
chylomicrons, chylomicron remnants, very low density lipoprotein and high density
lipoprotein subspecies. The ε4 allele is associated with increased total cholesterol levels and
the ε2 allele with decreased levels, and so APOE genotype would be expected to influence
the development of atherosclerosis and atherosclerotic vascular diseases.6 Possession of an
ε4 allele increases risk of ischemic heart disease by about one third.7 Our recent meta-
analysis found no convincing overall association between APOE and ischemic stroke (OR
1.11, 95% CI 1.01 to 1.22), but results from a few studies with information on ischemic
stroke subtypes suggested that ε4 allele-containing genotypes may specifically increase the
risk of large artery (atherothrombotic) ischemic stroke (OR 1.33), with no effect on other
subtypes (ORs between 0.86 and 1.06).4
Another way of assessing the association between APOE (or other genes) and large artery
atherothrombosis is to assess its effect on the quantitative intermediate phenotype of carotid
intima-media thickness (CIMT).8 CIMT is a good surrogate measure for subclinical
atherosclerosis, and increasing CIMT is directly associated with an increased risk both of
myocardial infarction and of stroke. Each 1 SD (0.2 mm) increase in common carotid artery
(CCA) IMT is associated with about a one third increase in the risk of myocardial infarction
and stroke.9 The association with stroke may arise mainly from a specific association with
large artery ischemic stroke, as CIMT has been found to be significantly higher in patients
with large artery compared with small artery (lacunar) ischemic stroke.10 Lowering LDL
cholesterol has also been shown to produce a reduction in CIMT.11 CIMT has reasonably
high heritability, although estimates vary between 30% and 86%.12-14
Many studies have now investigated the association between APOE genotype and CIMT.
We aimed to assess any association reliably, with a systematic review and meta-analysis.
Methods
Identification of Studies
We sought all available published studies of the association between APOE and CIMT in
humans. We used a comprehensive search strategy in Medline (1966 to the end of 2006) and
Embase (1980 to the end of 2006), which included MeSH terms and textwords for APOE
and for CIMT (see Appendix). We also checked the reference lists of all relevant articles for
further studies.
We included all studies that had measured the thickness of the intima-media of the carotid
artery, but excluded studies which only reported the presence or extent of atheroma or
plaque. We included studies among healthy subjects from the general population (low risk)
or groups of subjects with existing vascular disease or vascular risk factors, such as
hypertension, diabetes, hyperlipidemia, or coronary heart disease (high risk). We sought
articles in all languages. We excluded from our analyses otherwise relevant studies from
which the data required were not available in the relevant publication(s).
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Data Extraction
For each included study we extracted information on year of publication, country in which
the study was conducted, ethnicity of subjects, nature of the study population (eg, patients
with diabetes), total number of subjects, mean age and gender distribution of the subjects,
genotyping methodology, whether genotyping was done blind to CIMT and vice versa, and
the definition of CIMT. In addition, we extracted information on (or where possible tested
directly for) Hardy-Weinberg equilibrium. For each genotype or group of genotypes, we
extracted the mean CIMT and its standard deviation (SD). Where possible, we treated
studies that included both a high and a low risk group or more than one ethnic group as
separate substudies.
Two authors (L.P., N.A.M.G.) independently reviewed study eligibility and extracted the
information and data from each study, resolving any disagreements by discussion with a
third author (C.S.). Some articles reported several different measures of CIMT (eg, from
different carotid artery sites). Where a choice of measurement was available we chose the
one that was closest to our ideal: the mean CIMT of the left and right far wall of the CCA.
We chose this method because the CCA may give more reproducible results than the
internal carotid artery (ICA) because of its accessibility, and far wall measurements are
more accurate than near wall, which have to be performed at the trailing edge of the
ultrasound pulse.15
We defined genotype groups as E2 (ε3/ε2 or ε2/ε2), E3 (ε3/ε3), and E4 (ε3/ε4 or ε4/ε4),
and excluded any ε2/ε4 subjects from each study, as they could not be classified as E2 or
E4. These were extremely small in number (2% of all subjects), making it unlikely that their
inclusion or exclusion would affect the results.
Statistical Analysis
We first calculated the overall mean CIMT for each genotype group across all studies, and
then carried out meta-analyses using Cochrane RevMan software (version 4.2) comparing
the 2 genotype groups with the highest and lowest overall mean CIMT (E4 versus E2). We
calculated the mean CIMT difference between the E4 and E2 genotype groups for each
study, and pooled results using a random effects model. We used the I2 statistic to assess
heterogeneity between studies, where I2 estimates the percentage of variation between
studies that cannot be attributed to chance.16
We plotted the study-specific mean CIMT difference between E4 and E2 genotypes against
the standard error of this difference (a funnel plot) to check for the possibility of small study
bias. To assess the impact of study characteristics on the association we performed
prespecified subgroup analyses. We grouped the studies according to risk status of
individuals (those of high and low risk of vascular disease), study size (above or below the
mean total number of subjects), ethnicity (Eastern Asian, White, or Black African), and
method of measuring CIMT (ideal or not, where ideal measurements were those only from
the far wall of the CCA). We assessed the significance of differences between subgroups by
partitioning heterogeneity and using χ2 tests.
Results
Study Selection
Figure 1 shows the process of study selection and exclusion. Our search identified 490
articles, of which 32 were potentially relevant.17-48 Four studies were duplicates of other
included studies and so were excluded.39-42 Six studies had insufficient data presented to
be included in the analysis43-48 (including 2 that combined E2 and E3 genotype
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groups46,48). We therefore included 22 studies (increasing to 25 studies after 3 were split
into 2 substudies) in a total of 30 879 subjects in our analyses.
Study Characteristics
Details of the included studies are shown in the Table. Sample sizes ranged from 52 to 9304
with a mean of 1235. Subjects were mostly middle-aged to elderly. Most studies had
approximately equal proportions of males and females, although 5 included only men.
21,25,28,35,36 The studies were conducted in several European countries, the USA,
Australia, Japan, and China. Most subjects were included in low risk studies (healthy
subjects or general populations), whereas a smaller proportion were included in high-risk
studies (see Table). Most studies used a polymerase chain reaction/restriction fragment
length polymorphism method for genotyping, whereas 3 used isoelectric focusing,17,25,28 2
used polymerase chain reaction/allele specific oligonucleotide hybridization,23,31 and the 2
most recent studies used Taqman.37,38 Genotype group frequencies were fairly consistent
across all studies. No studies were found to depart from Hardy-Weinberg equilibrium,
although this was not reported and could not be tested directly in 5.20,23,24,33,34
All studies measured CIMT with B-mode ultrasound. The supplemental Table I, available
online at http://stroke.ahajournals.org, shows which segment of the carotid artery was
measured and how multiple measurements were combined to obtain the final CIMT value.
Only 2 studies stated that ultrasonography staff were blind to genotype data,28,34 and only
one stated that genotyping was carried out blind to the ultrasonography findings.29
Association Between APOE and CIMT
E4 genotypes had the highest mean CIMT across all studies (760 μm), the E3 genotype
group had an intermediate mean CIMT (751 μm), and E2 genotypes had the lowest mean
CIMT (743 μm; in keeping with their known effects on cholesterol levels). We therefore
compared mean CIMT for E4 versus E2 genotypes in our meta-analyses. Figure 2 shows the
study-specific and pooled results for the E4 versus E2 comparison in a total of 11989
subjects. Overall there was a highly significant pooled mean CIMT difference of 46 μm
(95% CI 29 to 62, P<0.00001). There was substantial heterogeneity between the studies
(I2=80%).
The funnel plot for the analysis was markedly asymmetrical, suggestive of small study
(presumably mainly publication) bias (supplemental Figure I, available online at http://
stroke.ahajournals.org).
Results of our subgroup analyses are shown in Figure 3. We found a substantially larger
pooled mean CIMT difference among high-risk compared with low-risk populations and in
Eastern Asian compared with White or Black African populations. However, we also found
that the pooled mean CIMT difference in smaller studies was more extreme than that in
larger studies (smaller studies [mean number of subjects analyzed 58]:93 μm, 95% CI 46 to
140; larger studies [mean number of subjects analyzed 1814]:17 μm, 95% CI 12 to 23,
P<0.00001; χ2 test for difference between the 2 subgroups: P<0.0001), suggesting the
existence of small study bias, consistent with the appearance of the funnel plot
(supplemental Figure I). There was little heterogeneity between the results of the larger
studies (I2=5%). Study size could explain the apparent difference in size of association
between high and low risk and between ethnic groups, because most studies in high risk
populations and among Eastern Asian subjects were small (mean number of subjects
analyzed in high-risk group 55, in low-risk group 813, in Eastern Asians 50, in other ethnic
groups 682).
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As CIMT was measured at a variety of sites within the carotid artery (supplemental Table I),
we split the data into those studies which used our preferred method (measuring only the far
wall of the CCA) and those that used any other method. Studies using our ideal CIMT
measurement method yielded less heterogeneous results and a smaller pooled mean CIMT
difference (16 μm, 95% CI 5 to 27), consistent with the estimated association in the larger
studies.
Robustness to Missing Data
We considered the impact of excluding relevant studies without available data for the E4
versus E2 genotype group comparison. Two relevant studies combined E2 and E3 data and
so could not be included in our analyses. One found no relationship between APOE and
CIMT among patients with noninsulin dependent diabetes, but found that ε4 allele-
containing genotypes increased CIMT by 0.14 mm compared with other genotypes in a
nondiabetic population.48 The other found no significant relationship between APOE and
CIMT.46 Four studies did not present mean and SD CIMT data by genotype or genotype
groups and so could not be included in any of our analyses. Three found no significant
association between APOE and CIMT,43-45 whereas the fourth found that E4 genotypes
were significantly more frequent than E2 genotypes in the subjects with higher CIMT
values.47 The total number of subjects in all genotype groups in all of these potentially
relevant additional studies was 1612, bringing to 32 491 the total possible number of
subjects that could have been included if data had been available. “Missing data” therefore
comprised only 5% of the total, making it very unlikely that including these studies would
have made a material difference to our results. Furthermore, the largest of these “missing
data” studies included 511 subjects.46 Therefore, none would have been categorized as a
large and so more reliable study (>1000 subjects).
Discussion
The results of our meta-analysis show a clear association between APOE and CIMT. In
keeping with the known effects of APOE on cholesterol levels, E2 genotypes had the lowest
CIMT, E3 genotypes an intermediate CIMT, and E4 genotypes the highest CIMT.
The overall pooled mean difference between E4 and E2 genotypes was 46 μm, but we found
evidence of small study bias, both from a funnel plot and a subgroup analysis based on study
size. Larger studies were far less heterogeneous, and found a substantially smaller—but still
highly statistically significant—mean CIMT difference between E4 and E2 genotypes of 17
μm. Thus, although the published literature taken as a whole probably overestimates the size
of the association, the consistency of direction of the association observed across the studies,
and the highly statistically significant findings for the larger, more reliable studies, strongly
suggests the presence of a true association.
Our subgroup analyses also suggested that the association between APOE genotype and
CIMT might be larger in high-versus low-risk subjects and in Eastern Asian populations. A
recent meta-analysis of the association between the angiotensin-converting enzyme
insertion/deletion polymorphism and CIMT also found a larger association in high risk
populations, and suggested that this may be attributable to an interaction with smoking.49,50
But, although the vascular risk and ethnicity subgroup differences in our meta-analysis could
conceivably be real, they may have arisen from confounding by study size, because the
studies in high-risk and Eastern Asian subjects were generally smaller than those in low-risk
and other ethnic groups, respectively.
The results of studies using ideal CIMT measurement methods were far less heterogeneous
than those using a nonideal measurement, suggesting that a consistent approach to CIMT
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measurement (using the mean of the right and left far wall measurements 1 cm below the
bifurcation) may lead to more reliable results that are comparable between studies. Although
the size of the association between APOE and CIMT varied with the location of
measurement, the results of individual studies showed that the direction of association was
consistent.
Several different genotyping methods were used in the studies, but any variations in the
resulting genotyping accuracy should not introduce any systematic error, and indeed we did
not find any influence of genotyping method on the size of the association between APOE
and ischemic stroke in a previous meta-analysis.4
Although our results concur with what we would expect from the known effect of APOE on
cholesterol levels, there may be other pathways through which APOE influences
atherosclerosis and so CIMT. Some studies included in our meta-analysis adjusted for
covariates, including cholesterol levels, in their analyses of the association between APOE
and CIMT. Whereas in some this resulted in loss or diminution of the association between
APOE and CIMT,25,32 in others the association between APOE and CIMT was preserved,
17,18,26,28,35,37,38 suggesting that APOE genotype may also influence CIMT
independently of its effects on cholesterol levels.
Summary
Our results have shown a modest association between APOE genotype and CIMT, even
though small study bias means that the published literature tends to overestimate the size of
this association. This suggests that APOE might modestly influence risk of large artery
ischemic stroke, and would support large case-control studies specifically to examine this
hypothesis. Further work is also required to determine whether or not the association we
have observed varies among different types of subjects according to ethnicity and vascular
risk status, and to further elucidate the mechanisms by which APOE may influence CIMT.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
Search strategy in Medline (similar strategy was designed for Embase)
1. carotid artery diseases/ or carotid artery thrombosis/ or carotid stenosis/ or
moyamoya disease/
2. carotid artery disease/ge or carotid artery thrombosis/ge or carotid stenosis/ge or
moyamoya disease/ge
3. carotid arteries/ or exp carotid artery, common/
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4. (carotid adj5 [atherosclero$ or arteriosclero$ or steno$ or imt or cimt or intima
media$ or ultrasound or plaque or sclero$ or atheroma$ or fatty streak or disease$
or disorder$]).tw.
5. 1 or 3 or 4
6. apolipoproteins/ or apolipoproteins e/
7. ([apolipoprotein$ adj e] or [apoprotein$ adj e] or apo-e or apo e or apoe).tw.
8. 6 or 7
9. 5 and 8
10. 2 or 9
11. limit 10 to humans
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Figure 1.
Flow diagram of study selection and exclusion process.
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Figure 2.
Study-specific and pooled mean differences of the CIMT between E4 and E2 genotypes
(ordered by publication date). The sizes of the squares are proportional to the statistical
weight given to each study. The horizontal lines represent 95% CI. The width of the
diamond represents the 95% CI of the pooled estimate. Heterogeneity between studies:
I2=80%.
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Figure 3.
Pooled mean differences of the CIMT between E4 and E2 genotypes: results for various
subgroups. The size of the squares is proportional to the number of subjects. Horizontal lines
represent 95% CI.
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